Analyst Ratings for Supernus Pharmaceuticals (SUPN) [Buys]
SUPN Rating Summary
SUPN Price Target Summary
- Highest: $43.00 (Piper Sandler)
- Lowest: $38.00 (Stifel)
- Average: $40.33
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
=
Avg. $ Target:
$40.33 (+35.8%)
* Over Last 12-Mos
Rating Score: 7.3 / 10
Percentile Rank: 78%
Rating Score: 7.3 / 10
Percentile Rank: 78%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 12/1/2021 | Jefferies » Updated 4/8/2024 |
Irene Buhalo | New Coverage | Buy (N/A) |
40.00 (N/A) |
30.41 (29.71) |
-2.3% | Details |
| 6/16/2020 | Piper Sandler » Updated 11/9/2023 |
David Amsellem | Upgrade | Overweight (Neutral) |
43.00 (42.00) |
22.83 (29.71) |
30.14% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
